Title : Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.

Pub. Date : 2016 May

PMID : 27123085






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 These results suggest that the 26S proteasome inhibitor bortezomib is more potent, compared with irinotecan and etoposide, in the androgen-insensitive and tumor protein p53-null cell line PC-3. Bortezomib tumor protein p53 Homo sapiens